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Abstract
Background and aims: Complications of cystic fibrosis–associated liver disease (CFLD) are a 
leading nonpulmonary cause of death. Transient elastography (TE) has recently been investigated to 
detect CFLD. This study reviews the current literature for TE in the detection CFLD. A meta-analysis 
was performed to determine the ideal liver stiffness measurement (LSM) cutoff.
Methods: PubMed, Medline, EMBASE and Web of Science were searched from inception until April 
2016 for publications involving the detection of CFLD with TE. Data were extracted using a fixed pro-
tocol (a priori design) including study design, population characteristics, probe size and AST Platelet 
Ratio Index (APRI).
Results: Diagnostic properties were summarized from six studies of 605 patients. Cutoff for LSM was 
determined using pooled data submitted by authors. The cutoff for LSM and APRI were ≥5.95 kPa and 
≥0.329 respectively, yielding a sensitivity, specificity and area under receiver operator characteristic of 
55%, 87%, 0.76, 52%, 93% and 0.84 for LSM and APRI, respectively. When LSM ≥5.95 kPa and APRI 
≥0.329, the sensitivity, specificity, positive predictive value and negative predictive value were 43%, 
99%, 92% and 87% with a diagnostic odds ratio of 74.9. A bivariate metaregression model showed that 
pediatric specific cutoffs for liver stiffness and APRI may not be necessary.
Conclusion: Individually, LSM and APRI have poor sensitivity but good specificity for detecting 
CFLD. They are most useful when combined. We propose that patients with LSM ≥5.95 kPa and APRI 
≥0.329 be investigated thoroughly for the presence of cystic fibrosis–associated liver disease.
Abbreviations: 
CF,  cystic fibrosis; 
CFLD,  cystic fibrosis–associated liver disease; 
CT,  computed tomography; 
MRI,  magnetic resonance imaging; 
TE,  transient elastography; 
LSM,  liver stiffness measurement; 
APRI,  AST platelet ratio index; 
HSROC,  hierarchical summary ROC; 
AUROC,  area under receiver operator characteristic; 
ROC,  receiver operator characteristic; 
ALT,  alanine aminotransferase; 
AST,  aspartate aminotransferase; 
GGT,  gamma-glutamyl transferase; 
IQR,  interquartile range; 
PPV,  positive predictive value; 
NPV,  negative predictive value; 
DOR,  diagnostic odds ratio
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Cystic fibrosis (CF) is a common autosomal recessive disease. 
Although pulmonary disease is the main cause of morbidity 
and mortality, cystic fibrosis–associated liver disease (CFLD) 
and its complications are increasingly recognized as a leading 
nonpulmonary cause of death (1). Up to one-third of individ-
uals with CF will develop CFLD, with about 5% of those with 
CFLD progressing to chronic liver failure (2). Current meth-
ods of detecting CFLD include monitoring of liver enzymes, 
ultrasonography, abdominal computed tomography (CT) and 
abdominal magnetic resonance imaging (MRI) (3). Although 
the gold standard for diagnosis is hepatic biopsy, this procedure 
is invasive, not without morbidity, prone to sampling error and 
impractical for population screening. Abdominal ultrasound 
is the most widely used imaging technique due to widespread 
accessibility and noninvasive nature. However, the utility of 
ultrasonographic assessment is limited by inter-observer vari-
ability and low sensitivity and specificity (3). Currently, the 
most widely accepted diagnostic criteria for CFLD are the 
EuroCare CFLD criteria, which includes ≥2 of the following: 
persistent abnormal liver biochemistry over 12 months, hep-
atomegaly and/or splenomegaly, or ultrasound abnormalities 
(3). Transient elastography (TE) is a novel technique used for 
liver stiffness measurement (LSM) as a surrogate of liver fibro-
sis. It has been validated for use in various forms of chronic 
liver disease in adults including hepatitis B and C, primary bil-
iary cirrhosis, and nonalcoholic fatty liver disease (4). Liver 
stiffness measurements may be useful in the clinical setting 
for detecting and monitoring CFLD because it is a noninva-
sive, relatively inexpensive, fast, and less resource-intensive 
technique with less inter-observer variability compared with 
ultrasonography (3). Few studies have evaluated the role of TE 
in the detection of CFLD (5–11), with limited studies specif-
ically evaluating pediatric patients (5, 6, 11). The purpose of 
this study is to perform a systematic review to determine the 
diagnostic properties of TE in the detection of CFLD in adult 
and pediatric populations compared with currently accepted 
international CFLD diagnostic criteria. A  single indicator of 
test performance, the diagnostic odds ratio (DOR), was also 
reported (12). Our secondary objective was to perform a 
meta-analysis to determine the most appropriate LSM cutoff 
for the detection of CFLD using data submitted by original 
authors from included studies. In addition, cutoffs for AST 
platelet ratio index (APRI), when available, were calculated 
to determine if this could augment the diagnostic properties 
of LSM.
METHODS
Search Strategy
Medline (Pubmed), Medline (OvidSP), EMBASE, Web of 
Science, Cochrane Database of Systematic Reviews and Google 
Scholar were searched from database inception to present, 
using combinations of the following key terms: cystic fibrosis, 
liver disease, cystic fibrosis associated liver disease, hepatic dis-
ease, transient elastography, Fibroscan, and elasticity imaging 
techniques. The literature search was performed on April 22, 
2016 (Appendix 1).
Manual searches of reference list from primary studies were 
performed to locate any missing studies from initial electronic 
search strategies. Abstracts and proceedings from the American 
Association for the Study of the Liver, European Association for 
the Study of the Liver and Digestive Disease Week annual meet-
ings were also reviewed from 2011 to 2016. This time period 
was chosen because the currently used criteria for the diagno-
sis of CLFD was published in 2011. Prior to this, diagnosis of 
CFLD was not well defined. 
Selection of Studies
Inclusion Criteria.
Studies were considered if they included the current EuroCare 
criteria defining CFLD or similar parameters. Liver stiffness 
measurement was measured via transient elastography and data 
available to construct a 2 × 2 table of test performance for anal-
ysis. Articles assessing LSM in multiple forms of chronic liver 
disease were included if CFLD-specific data could be extracted. 
Studies with adult and pediatric data were also included.
Case definition of CFLD was based on the EuroCare CFLD 
criteria (≥2 of the following: persistent abnormal liver bio-
chemistry over 12 months, hepatomegaly or splenomegaly, or 
ultrasound abnormalities). 
Exclusion Criteria.
Non-English articles, letters, editorials, comments, review arti-
cles or case report formats were excluded. 
Data Extraction Protocol
Two independent reviewers (SL, JD) reviewed the titles and 
abstracts of all search results. Relevant articles were inde-
pendently reviewed for inclusion and exclusion criteria. Any 
disagreement was resolved through consensus between the 
reviewers. Data extracted included first author, country of first 
author, year of publication, study design, number of patients, 
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patient characteristics (pediatric, adult or mixed and number 
of patients with CFLD), median LSM with interquartile ranges 
(IQR) (if available), optimal cutoff value to detect CFLD, area 
under receiver operator characteristic (AUROC), sensitivity 
and specificity. Where available, aspartate APRI information 
was also extracted. Corresponding authors of included studies 
were contacted to request data from their study. This included 
age, sex, presence of CFLD (as classified by submitting authors), 
alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyl transferase (GGT), platelet count, 
pancreatic sufficiency, ultrasound findings and LSM. The upper 
limits of normal for liver enzymes and platelet counts from 
respective laboratories were also requested.
Quality Assessment
The quality of the diagnostic studies was evaluated using 
the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2). This tool has been validated to assess the inter-
nal and external validity of diagnostic accuracy studies included 
in systematic reviews (13, 14). 
Statistical Analysis 
Meta-analysis.
The eligible studies were summarized with sensitivity and spec-
ificity described. A hierarchal summary receiver operator curve 
(HSROC) curve was calculated using a bivariate random effects 
model accounting for study-specific sensitivity and specificity 
using STATA 13.1 (STATACorp LP, College Station, TX, USA) 
and Revman 5.2 (The Cochrane Collaboration, Copenhagen, 
Denmark). The technique models the true positives and 
true negatives as a bivariate response with random effects for 
accounting for heterogeneity. Based on the same hierarchical 
model, a meta-regression was used to investigate the effect of 
pediatric and adult groups on the estimation.
To estimate the diagnostic value of TE for the diagnosis of 
CFLD, a weighted summary DOR, as a single indicator of test 
performance, was determined using STATA. I2 and the forest plot 
were generated with R v3.4.0 (R Core Team, Vienna, Austria).
Pooled analysis.
The author SL contacted corresponding authors of eligible 
studies to request their original data. Individual patient data 
were normalized to the current EuroCare CFLD criteria to 
facilitate a pooled analysis. Only patients with valid (≥60% 
successful measurements) and reliable (IQR/median  ≤0.30) 
LSMs were included. Age, liver enzymes, platelets, LSM and 
APRI were compared between groups using the Wilcoxon-
Rank sum test using STATA 13.1 (STATACorp LP, College 
Station, TX, USA).
Sex and pancreatic sufficiency between groups were 
compared using Chi-squared and Fisher Exact methods, 
respectively. Optimal cutoffs for LSM and APRI were assessed 
by the receiver operating characteristic (ROC) (STATA 13.1). 
This was calculated as sensitivity versus 1-specificity (Microsoft 
Excel 2016). The optimal cutoff was determined by the point 
yielding the maximum sum of sensitivity and specificity. The 
AUROC was expressed. Sensitivity, specificity, positive predic-
tive value (PPV), negative predictive value (NPV) and accu-
racy were calculated for these cutoffs. Diagnostic odds ratio was 
also calculated for selected cutoffs to evaluate test performance.
Stratified analysis of children (<18  years) and adults 
(≥18 years) was also performed.
RESULTS
Search Results
The online search revealed 116 published articles (Figure  1). 
After removal of duplicates, 69 abstracts were manually 
reviewed. Subsequently, 36 abstracts were excluded due to the 
following reasons: 16 were unrelated to TE, eight were unrelated 
to CFLD and 12 were review articles. The remaining 33 abstracts 
were reviewed as full text published articles. Subsequently, 27 
studies were excluded, 13 did not use the current EuroCare 
CFLD criteria, nine articles and conference abstracts did not 
contain sufficient information to extract required data, three 
conference abstracts were subsequently published into a study 
which was included in analysis (i.e., duplicate), and two were 
letters to editor. Six studies were included in the final analysis. 
Of note, a Google scholar search, up to page 10, did not reveal 
additional relevant articles not already found by our described 
search method.
The included studies are described in Table 1. Studies included 
authors from Canada, Australia, Germany and Belgium. Three 
studies had exclusively adult patients (8, 9, 11) and three stud-
ies had a mixed population of adults and pediatrics (7, 10, 15). 
A  total of 633 patients, comprising 460 (73%) adult and 173 
(27%) pediatric patients, were included in the meta-analysis.
Quality Assessment
When QUADAS-2 criteria were applied, studies had low to 
unclear risk of bias, except one (16) (Figure 2). The reference 
standard bias was classified as unclear in all studies because 
none of the studies explicitly stated that the interpretation of 
the reference EuroCare criteria was made independently from 
the LSM data as measured by TE. One study had a high risk 
of patient selection bias because only patients with liver abnor-
malities were referred for assessment (9). All studies had low 
applicability concerns.
Diagnostic Properties of TE in the Detection of CFLD
The diagnostic properties for TE in the detection of CFLD 
with varying cutoffs are summarized in Table 2. Qualitatively, 
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the range of sensitivities and specificities for using TE to 
detect CFLD were 46% to 100% and 76% to 92%, respec-
tively. The calculated summary DOR as a single indicator 
of test performance was 14.9 (95% CI, 6.06–36.5; Q=5.01, 
P=0.414), with a low degree of heterogeneity between studies 
(Figure 3).
Table 1. Summary of included studies
Author Year Country Study Design Population Number of Patients Number of CFLD
Friedrich- Rust et al. 2013 Germany Prospective Mixed 106 24
Karlas et al. 2012 Germany Prospective Adult 55 14
Kitson et al. 2013 Australia Prospective Adult 50 25
Rath et al. 2012 Germany Prospective Mixed 145 68
Sadler et al. 2015 Canada Prospective Adult 127 18
Van Biervliet et al. 2016 Belgium Prospective Mixed 150 20
Total 633 169
Figure 1. PRISMA search method.
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In order to determine the effect of being a child or adult on the 
diagnostics of LSM for individual study cutoffs, we conducted a 
meta-regression adjusting for the covariate ‘adult/pediatric’. In 
the studies that had both pediatric and adult patients, categori-
zation into pediatric or adult did not have any effect on sensitiv-
ity (P=0.83) nor false positive rates (P=0.53).
The effect of being or adult on the diagnostic properties of 
APRI could not be analyzed as APRI cutoffs were only reported 
in adult studies.
Pooled Analysis
Data for 644 patients were submitted by collaborating authors 
for pooled analysis. Author SV submitted eight more patients 
than her initial cohort of 150 (15). Author ER submitted three 
more than the initial 145 patients (10). After normalizing the 
data between studies, 39 patients were excluded from analysis, 
24 had unreliable measurements, and 15 had failed LSM mea-
surement. By standardizing all data to current CFLD criteria, 
one patient was recategorized into the CFLD group. The pooled 
analysis of 605 patients meeting eligibility criteria is summa-
rized in Table 3.
The median age was 24  years old, with 293 females (48%), 
and 171 patients (28%) had CFLD. The patients with CFLD 
had higher median LSM (6.3 kPa versus 4.4 kPa) (P<0.005) 
and a lower platelet count (258 × 109/L versus 307 × 109/L) 
(P<0.005). As expected, the ALT, AST and GGT were all 
higher in the CFLD group compared with the non-CFLD 
group: 30 U/L, 30 U/L 27 U/L versus 19 U/L versus 24U/L, 
14 U/L (P<0.005), respectively. The APRI was calculated for 
379 patients. The median APRI value was higher in patients 
with CFLD compared with non-CFLD: 0.330 versus 0.151 
(P<0.005).
The diagnostic properties of calculated cutoff values from the 
pooled analysis were summarized in Table 4. The optimal LSM 
cutoff was ≥5.95 kPa yielding a sensitivity, specificity, PPV, 
NPV, AUROC and accuracy of 55%, 87%, 65%, 83%, 0.76 and 
78%, respectively (Figure  4A). The optimal APRI cutoff was 
≥0.329, yielding sensitivity, specificity PPV, NPV, AUROC and 
accuracy of 52%, 93%, 66%, 88%, 0.78 and 84% (Figure  4B). 
A meta-regression showed no effect on the sensitivity (P=0.47) 
nor false positive rate (P=0.37) based on being an adult or child 
with the pooled LSM cutoffs.
Similarly, the meta-regression did not show an effect for the 
calculated APRI cutoff sensitivity (P=0.79) and false positive 
rate (P=0.11).
Combining LSM and APRI
When both LSM and APRI values were available for analysis, 
if the LSM is ≥5.95 kPa and APRI ≥0.329, then the sensitivity, 
specificity, PPV, NPV and accuracy were 43%, 99%, 92%, 87% 
and 0.87, respectively.
Pediatric subgroup analysis.
In the subgroup analysis of 167 pediatric patients, 45 (27%) 
had CFLD. The median age was 10 years. Eighty-four patients 
were female (50%). The median LSM for pediatrics with CFLD 
was higher, 6.4 kPa versus 4.4 kPa (P<0.005). Similarly, the 
ALT, AST and GGT were all significantly elevated in CFLD 
patients compared with non-CFLD patients. Platelets were 
also decreased in the pediatric CFLD patients compared with Figure 2. QUADAS 2 summary of methodological quality.
Table 2. Summary of diagnostic properties of included studies
Study LSM Cutoff
(≥kPa)
TP FP FN TN Sensitivity
% (95% CI)
Specificity
% (95% CI)
DOR 
(95% CI)
Friedich-Rust et al. 2013(7) 7.1 11 7 13 71 46 (26–67) 91 (82–96) 8.5 (2.8–26.2)
Karlas et al. 2012(11) 5.9 6 1 8 34 43 (18–71) 97 (85–100) 25.5 (2.7–242.6)
Kitson et al. 2013(16) 5.5 19 2 6 23 76 (55–91) 92 (74–99) 36.4 (6.6–201.7)
Rath et al. 2012(10) 5.5 35 14 32 61 52 (40–65) 81 (71–89) 4.8 (2.2–10.1)
Sadler et al. 2015(8) 5.3 12 19 6 90 67 (41–87) 83 (74–89) 9.5 (3.2–28.4)
Van Biervliet et al. 2016(15) 6.8 18 11 2 119 90 (68–99) 92 (85–96) 97.4 (19.9–475.6)
TP: True Positive, FP: False Positive; FN: False Negative; TN: True Negative
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non-CFLD patients 283 × 109/L versus 343 × 109/L (P=0.007). 
The APRI for 82 pediatric patients showed a higher median 
APRI in CFLD patients compared with non-CFLD patients, 
0.436 versus 0.130 (P<0.005).
A significantly lower proportion of CLFD patients were pan-
creatic insufficient compared with non-CFLD patients: 49% 
versus 69% (P=0.019).
Adult sub-group analysis.
In the subgroup analysis of 442 adult patients including 128 
(30%) CFLD patients, the median age was 28 years. There were 
209 females (47%). The median LSM for adults with CFLD 
was higher, 6.2 kPa versus 4.3 kPa (P<0.005). Similarly, the 
ALT, AST and GGT were all significantly elevated in CFLD 
patients compared with non-CFLD patients. Platelets were 
also decreased in CFLD patients compared with non-CFLD 
patients: 246  ×  109/L versus 292  ×  109/L (P<0.005). The 
APRI for 297 adults showed a higher median APRI in CFLD 
patients compared with non-CFLD patients, 0.330 versus 
0.169 (P<0.005).
In contrast to the pediatric group, a significantly higher pro-
portion of CLFD patients were pancreatic insufficient com-
pared with non-CFLD patients: 79% versus 63% (P<0.005).
DISCUSSION
Optimal screening in the CF population for CFLD continues 
to be a challenge. Current recommendations include routine 
bloodwork and abdominal ultrasound, which have limited 
sensitivity and specificity (3). Although these methods are 
noninvasive, they can be anxiety-provoking and time-consum-
ing, especially in the pediatric population. When there is diag-
nostic uncertainty, a liver biopsy is required, which can lead to 
morbidity and mortality. In pediatrics, a liver biopsy typically 
requires a general anesthetic, which may be further compli-
cated by a patient’s respiratory status. Liver stiffness measure-
ment measured by TE offers a quick, noninvasive alternative to 
the traditional methods of detecting CFLD. This tool may add 
further diagnostic clarity to avoid the need for biopsy. Several 
small studies have attempted to address the optimal cutoff and 
diagnostic properties of LSM to detect CFLD.
In this systematic review and meta-analysis, we have sum-
marized the diagnostic properties of LSM as measured by TE 
for the detection of CFLD. To our knowledge, this is the first 
review of the literature and the largest pool of raw data from 
independent cohort studies. By evaluating this data submitted 
by contributing authors, standardization to current EuroCare 
CFLD criteria could be applied to all patients. Our primary out-
come was to determine the usefulness of TE in the detection 
of CFLD. As described in the HSROC, LSM has high specific-
ity. The summary DOR for TE in the detection of CFLD was 
robust at 14.9 (95% CI, 6.06–36.5). This is in a similar range to 
a previous meta-analysis assessing TE and detecting fibrosis in 
hepatitis C patients, showing that TE had a DOR of 7.6 to 10.2 
for detecting F2–F4 fibrosis (17).
Our secondary outcome was to determine the optimal cut-
off for the detection of CFLD by pooling data from all eligible 
studies. Our cutoff of ≥5.95 kPa was within the lower range for 
the detection of F2 fibrosis in the published literature for vari-
ous other liver diseases (18). This comparison should be inter-
preted with caution because the cutoff for CFLD was intended 
to detect disease and not to stage degree of fibrosis. Recent lit-
erature also suggests that different diseases may require differ-
ent cutoffs (19). This may be especially relevant as steatosis is 
a manifestation of CFLD. Steatosis can decrease the velocity of 
the acoustic wave, thus decreasing the LSM value.
Our pooled cutoff had a specificity of 87% (95% 
CI, 83–89%) which was within the expected range as 
Figure 3. Summary figures of 6 pools studies with 633 pediatric and adult patients with cystic fibrosis. A) Forest plot of diagnostic odds ratios of included studies. B) Hierarchical summary 
receiver operator characteristic of included studies.
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determined by the HSROC. The value in the LSM may 
be in its specificity and high negative predictive value. 
As such, if LSM is below the cutoff, it is unlikely that the 
patient has CFLD. This is consistent with the role of TE in 
ruling out advanced disease in other forms of chronic liver 
disease (20).
Table 3. Summary of compiled patient characteristics submitted by authors
 All patients
All (n=605) Non CFLD (n=434) CFLD (n=171) P value
Age (years) 24 (16–33) 24 (16–33) 25 (17–33) 0.97
Female 291 (48%) 210 (48%) 83 (48%) 1.00
LSM (kPa) (n=605) 4.6 (3.7–5.9) 4.4 (3.6–5.2) 6.3 (4.4–10.6) <0.005
ALT (U/L) (n=598) 21 (16–30) 19 (15–26) 30 (20–47) <0.005
AST (U/L) (n=455) 25 (20–31) 24 (19–29) 30 (24–40) <0.005
GGT (U/L) (n=495) 16 (11–28) 14 (10–21) 27 (16–60) <0.005
PLT (x 109/L) (n=523) 298 (243–366) 307 (257–371) 258 (184–346) <0.005
Pancreatic Insufficient (n=555) 368 (66%) 264 (65%) 104 (70%) 0.26
APRI (n=379) 0.173 (0.116–0.260) 0.151 (0.107–0.220) 0.330 (0.195–0.637) <0.005
Pediatric Subgroup
All (n=167) Non CFLD (n=122) CFLD (n=45) P value
Age (years) 10 (7–13) 10 (7–14) 10 (8–13) 0.89
Female 84 (50%) 59 (48%) 25 (56%) 0.49
LSM (kPa) (n=167) 4.6 (3.8–5.7) 4.4 (3.7–5.2) 6.4 (5.1–15.4) <0.005
ALT (U/L) (n=162) 21 (15–30) 19 (14–24) 31 (20–52) <0.005
AST (U/L) (n=94) 28 (24–32) 27 (23–31) 33 (27–47) 0.007
GGT (U/L) (n=144) 13 (10–20) 11 (9–15) 20 (15–35) <0.005
PLT (x 109/L) (n=155) 331 (269–395) 343 (283–398) 283 (220–387) 0.007
Pancreatic Insufficient (n=165) 105 (66%) 83 (69%) 22 (49%) 0.019
APRI (n=82) 0.135 (0.107–0.188) 0.130 (0.106–0.161) 0.436 (0.197–0.687) <0.005
Adult Subgroup
All (n=438) Non CFLD (n=314) CFLD (n=128) P value
Age (years) 28 (22–37) 28 (22–37) 28 (23–36) 0.89
Female 207 (47%) 151 (48%) 58 (45%) 0.60
LSM (kPa) (n=438) 4.5 (3.7–6.0) 4.3 (3.5–5.2) 6.2 (4.35–9.5) <0.005
ALT (U/L) (n=436) 21 (16–32) 20 (15–27) 28 (20–43) <0.005
AST (U/L) (n=361) 24 (19–30) 23 (19–28) 28 (23–39) <0.005
GGT (U/L) (n=350) 18 (12–32) 16 (10–24) 31 (18–63) <0.005
PLT (x 109/L) (n=368) 284 (232–349) 292 (251–356) 246 (171–333) <0.005
Pancreatic Insufficient (390) 263 (67%) 181 (63%) 82 (79%) <0.005
APRI (n=297) 0.185 (0.118–0.278) 0.169 (0.111–0.235) 0.330 (0.195–0.603) <0.005
Median (IQR)
Table 4. Diagnostic properties of cutoffs derived from compiled data
Optimal Cutoff Sensitivity Specificity PPV NPV AUROC Accuracy
≥5.95 kPa 55 (47–62) 87 (83–89) 65 (54–70) 83 (79–86) 0.76 (0.71–0.80) 0.78 (0.75–0.81)
≥0.329 52 (40–63) 93 (90–96) 66 (53–78) 88 (84–91) 0.78 (0.71–0.84) 0.84 (0.80–0.88)
LSM ≥5.95 kPa AND APRI 
≥0.329
43 (32–55) 99 (97–100) 92 (78–98) 87 (83–90) n/a 0.87 (0.84–0.91)
Value (95% CI)
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Another useful parameter may be the APRI. Like LSM, the 
APRI has good specificity, 93% (95% CI, 90–96%). This may be 
useful for centers without TE capabilities because components 
of the APRI can be calculated from standard complete blood 
counts and liver biochemistry.
Finally, if both LSM and APRI are combined, this may be 
the most useful for the detection of CFLD. If the LSM was 
≥5.95kPa and APRI ≥0.329, then there was a high PPV and 
NPV. The DOR for combining positive LSM and APRI was 
75 (95% CI, 22–253). This is within a comparable range to the 
DOR of 74.9 (95% CI, 38.7–145.1) when LSM is used in the 
detection of cirrhosis in patients with chronic hepatitis C (17).
Our analysis has several strengths. First, literature for LSM 
in detecting pediatric CFLD is limited. At the time of the lit-
erature review, there were no studies determining the optimal 
LSM cutoff for the detecting CFLD exclusively in the pediatric 
population. By pooling pediatric data from studies with mixed 
populations, we determined through a meta-regression that 
pediatric specific cutoff may not be necessary. This notion is 
supported by a large pediatric study where age was not found 
to affect LSM (21). A more recent study did reveal age-related 
LSM differences; however, this group used an M probe for all 
patients studied, which may not have been appropriate (22).
Another strength to our study is that we calculated LSM 
cutoffs from individual patient data submitted by authors. 
Having individual data allowed for the current internation-
ally accepted CFLD criteria to be applied to all patients, thus 
decreasing heterogeneity. Some studies included patients 
with unreliable LSM to be included in their cutoff measure-
ments. With our pooled data, only patients with reliable LSM 
were analyzed, therefore a more accurate LSM cutoff would 
be expected.
It has been hypothesized that pancreatic insufficiency may be 
associated with CFLD (23). Pancreatic insufficiency differed 
among those with CFLD and without CFLD in the subgroup 
analysis. Pancreatic insufficiency was more prevalent in the adult 
CFLD group. In contrast, in the pediatric group, with a median 
age of 10, CFLD patients were more likely to be pancreatic suf-
ficient. The reason for this is unclear as most patients develop 
pancreatic insufficiency within the first year of life (24). It was 
unclear from the data submitted by the authors how pancreatic 
insufficiency was diagnosed; thus it was a potential confounder. 
Further studies are needed to further elucidate this new finding.
The prevalence of CFLD within our pooled cohort was 28%, 
which is in keeping with the current literature (3). Therefore, 
our proposed LSM and APRI cutoffs can be applied broadly to 
the CF population and can expect similar positive and negative 
predictive values.
The quality of included studies was good, but all had an 
unclear reference standard bias. That is, it is unclear whether the 
EuroCare CFLD criteria were determined without knowledge 
of the LSM. Overall, the concern for this is low because it is 
unlikely that prior knowledge of LSM would affect interpreta-
tion of CFLD criteria; therefore, the risk of bias is low.
As expected, the liver enzymes suggestive of liver injury (ALT 
and AST) were higher in the CLFD group compared with the 
Figure 4. Receiver Operator Curves for pooled data analysis. A) LSM cut-off determined by pooled data from 605 pediatric and adult patients with cystic fibrosis. B) APRI cut-off determined by 
pooled data from 379 pediatric and adult cystic fibrosis patients.
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non-CFLD group. The elevated LSM in CFLD patients may 
reflect not only fibrosis but also liver inflammation.
A limitation of our study was the inconsistency of probes used 
in the studies. Manufacturer recommendation for probe sizes are 
based on weight and chest circumference. In our analysis, differ-
ent studies used different probe sizes. For example, one study 
used a medium probe in all patients (15), which also included 
pediatric patients, while another used different probes based on 
patient weight (10). There is emerging literature that different 
probe sizes may yield statistically significant differences in LSM 
in the pediatric population (21), although the clinical signifi-
cance is unknown. In addition, the duration of fasting before 
the LSM was also unclear from the studies, which may have also 
affected LSM. As TE is increasingly used, guidelines have been 
recently published to standardize technique (20).
Another limitation was that genotypic information was not 
available; therefore, any genotypic correlation with CFLD 
would not be analyzed.
There was also the risk of misclassification bias due to treat-
ment effects. Ursodoxycholic acid is a frequently used medi-
cation to treat CFLD. In our analysis, medication history was 
not available. Therefore, patients with CFLD who improved 
on ursodeoxycholic acid may have been misclassified as not 
having CFLD.
The primary objective of our study was to summarize the 
diagnostic properties of LSM for the detection of CFLD. 
Secondarily, we sought to determine the optimal LSM cutoff. 
The APRI information was often available and, therefore, was 
included in our analysis to determine if this noninvasive index 
could augment LSM in the detection of CFLD. Our primary lit-
erature review did not include APRI as one of the search terms, 
and therefore, publications reviewing APRI in the detection of 
CFLD were likely missed. This may be an area of future study. 
Despite this limitation, we feel that our APRI cutoff based on 
379 patients still provides valuable information.
Steatosis is a manifestation of CFLD which may affect LSM; 
however, ultrasonographic information regarding steatosis was 
not available to analyze. A  future area of investigations would 
include using controlled attenuation parameter (CAP) in the 
assessment of CFLD. Using the CAP to quantify the degree of 
steatosis may improve the diagnostic value of TE in the detec-
tion of CFLD. Furthermore, determining different subtypes of 
liver manifestations (i.e., steatosis only versus fibrosis only) of 
CF patients may provide further insight into the progression 
of CFLD.
Lastly, data was not unable to segregate LSM or APRI cut-
offs with complications of portal hypertension. Two small 
studies showed that an LSM of >8.9–12.0 kPa may predict the 
presence of esophageal varices (6, 9). Aqul et al. recently pub-
lished a large pediatric and young adult cohort using LSM to 
detect the presence and severity of CFLD (25). They found 
an optimal LSM cutoff of >6.2 kPa for detecting CFLD with 
portal hypertension. However, the criteria used for CFLD in 
this cohort was very broad and was not consistent with the cur-
rently accepted diagnostic criteria. Furthermore, as the authors 
discussed the limitations of their study, one of the criteria used 
for portal hypertension was splenomegaly on physical exam-
ination, which may not be accurate, as lung hyperinflation in 
the CF population may cause the spleen to be palpable. To our 
knowledge, other clinically relevant CFLD end points such has 
liver-related mortality or time to liver transplantation have not 
been studied in the context of LSM but would be a valuable area 
of future studies.
CONCLUSIONS
To our knowledge, this is the largest cohort of CF patients used 
to calculate the diagnostic properties and optimal cutoffs for 
LSM and APRI in detecting CFLD. These methods have low 
sensitivity but good specificity. The strength of these tests is in 
their NPV; therefore, patients with LSM <5.95 kPa or APRI 
<0.329 are unlikely to have CFLD, especially if neither are 
above the cutoff. However, if both LSM is ≥5.95 kPa and APRI 
is ≥0.329, these patients are likely to have CFLD and should be 
thoroughly investigated.
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